Breaking News
Black Friday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

The Biotech Sector's Underperformance May Be About To Get Worse

By Michael KramerStock MarketsJul 19, 2019 03:10AM ET
The Biotech Sector's Underperformance May Be About To Get Worse
By Michael Kramer   |  Jul 19, 2019 03:10AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

The S&P Biotechnology Select Industry Index has fallen by around 1.5% in July, underperforming the broader S&P 500’s gain of over 1.5%. Drug prices have once again become a political topic as the U.S. 2020 Presidential Election comes into focus, weighing down hard on the sector.

The bad news is that the sector's underperformance may not only continue but get worse. Using the SPDR S&P Biotech ETF (NYSE:XBI) as a proxy for the Biotech Index, it shows that the ETF could see a significant drop based on a technical analysis by as much as 8% from its current price of $86.83.

SPX biosector
SPX biosector

Technical Break Down

The chart shows that the ETF has been hovering around an important level of technical support at $85.25. However, the bad news is that all signs are suggesting the level of support may not hold. The ETF has already fallen below an uptrend which began at the end of May, which may now also act as resistance should the ETF rise. Additionally, it would appear a descending triangle may be forming, a bearish technical pattern. This would imply the stock may fall below the support level at $85.25, pushing the ETF to around $80, its next level of technical support.

The relative strength index is also beginning to trend lower since peaking near overbought levels at 70 in the beginning of March, suggesting that bullish momentum is leaving the ETF.

XBI chart
XBI chart

Drug Prices

One reason the sector has struggled in July is the debate around reducing the cost of drug prices in the U.S. Recently, President Donald Trump proposed a plan that would have limited the rebates a drug company could pay to benefit managers under Medicare. However, despite that plan being canceled, the sector has still struggled, because investors are nervously waiting for what may be the next attempt to bring down those drug prices.

The Presidential Election May Weigh

The negative focus on high drug prices killed the sector during the 2016 presidential election. From the end of July in 2015 until the election in 2016, the S&P Biotechnology Select Industry Index fell by over 32%. That is compared to an increased by about 2% on the S&P 500. Anxiety about threats to rein in drug prices, and the uncertainty of how that would happen, caused investors to flee the sector.

SPX biotech
SPX biotech

Once the election was over and the talk died down, the index went on to rise by 65% from Nov. 8 through July 31, 2018. That was more than double the pace of the S&P 500's increase of 31.6% over the same time.

The Start Of Something Steeper

It may be too early to tell if a Biotech sector pullback is the start of something bigger and longer-term. However, it seems very clear it's on the mind of investors: the sector's underperformance didn’t just start in July. The group has been struggling since the beginning of April, having fallen by nearly 5%, versus the S&P 500's gain of over 4.5%.

Should drug pricing become a centerpiece of the presidential election in 2020, the recent underperformance could turn into something much more severe. Potentially as damaging as the one seen four years ago.

At this point, it isn’t even clear how much politics will play into the performance of the biotechnology sector. However, at the very least we can conclude that the four months of underperformance suggests investors are definitely getting very jittery.

The Biotech Sector's Underperformance May Be About To Get Worse

Related Articles

Trading Point
Can Anything Stop The Stock Market? By Trading Point  - Nov 26, 2021

Stock markets have gone on an absolute rampage this year. The problem is that the factors that initially fueled this rally - heavy government spending and endless central bank...

The Biotech Sector's Underperformance May Be About To Get Worse

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
hu ssein
hu ssein Jul 19, 2019 11:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
watch the gap at $75 on xbi...
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email